Targets › FAM19A5
1 program from 1 company in 1 trial: 1 Phase 1; Other.
Acts as a chemokine-like protein by regulating cell proliferation and migration through activation of G protein-coupled receptors (GPCRs), such as S1PR2 and FPR2 (By similarity). Stimulates chemotactic migration of macrophages mediated by the MAPK3/ERK1 and AKT1 pathway (By similarity). (UniProt, Q7Z5A7)
Open in Phaseline: the race on FAM19A5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neuracle Science | NS101 anti-FAM19A5 antibody; synapse organizer and reverser of synapse dysfunction | FAM19A5 | Phase 1 | Seneorineural Deafness | – |
Seneorineural Deafness (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.